Targeting the Androgen Receptor

被引：49

作者：

Friedlander, Terence W. ^{[1
]}

Ryan, Charles J. ^{[1
]}

机构：

[1] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, Div Genitourinary Med Oncol, San Francisco, CA 94143 USA

来源：

UROLOGIC CLINICS OF NORTH AMERICA | 2012年 / 39卷 / 04期

关键词：

Castration-resistant prostate cancer; Androgen receptor; Abiraterone acetate; Orteronel; Galeterone; MDV3100; ARN-509; EPI-001; INDEPENDENT PROSTATE-CANCER; TUMOR-CELL LINES; ANTIANDROGEN WITHDRAWAL; PHASE-III; DEPRIVATION THERAPY; HORMONAL-THERAPY; GROWTH-FACTOR; OPEN-LABEL; CASTRATION; ACTIVATION;

D O I：

10.1016/j.ucl.2012.07.003

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Androgen receptor (AR)-mediated signaling is critical to the growth and survival of prostate cancer. Although medical castration and antiandrogen therapy can decrease AR activity and lower PSA, castration resistance eventually develops. Recent work exploring the molecular structure and evolution of AR in response to hormonal therapies has revealed novel mechanisms of progression of castration-resistant prostate cancer and yielded new targets for drug development. This review focuses on understanding the mechanisms of persistent AR signaling in the castrate environment, and highlights new therapies either currently available or in clinical trials, including androgen synthesis inhibitors and novel direct AR inhibitors.

引用

页码：453 / +

页数：13

共 52 条

[1] Regression of Castrate-Recurrent Prostate Cancer by a Small-Molecule Inhibitor of the Amino-Terminus Domain of the Androgen Receptor [J].

Andersen, Raymond J. ;

Mawji, Nasrin R. ;

Wang, Jun ;

Wang, Gang ;

Haile, Simon ;

Myung, Jae-Kyung ;

Watt, Kate ;

Tam, Teresa ;

Yang, Yu Chi ;

Banuelos, Carmen A. ;

Williams, David E. ;

McEwan, Iain J. ;

Wang, Yuzhou ;

Sadar, Marianne D. .

CANCER CELL, 2010, 17 (06) :535-546

[2] Src kinase potentiates androgen receptor transactivation function and invasion of androgen-independent prostate cancer C4-2 cells [J].

Asim, M. ;

Siddiqui, I. A. ;

Hafeez, B. B. ;

Baniahmad, A. ;

Mukhtar, H. .

ONCOGENE, 2008, 27 (25) :3596-3604

[3]

Bevan CL, 1999, MOL CELL BIOL, V19, P8383

[4] External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study [J].

Bolla, Michel ;

Van Tienhoven, Geertjan ;

Warde, Padraig ;

Dubois, Jean Bernard ;

Mirimanoff, Rene-Olivier ;

Storme, Guy ;

Bernier, Jacques ;

Kuten, Abraham ;

Sternberg, Cora ;

Billiet, Ignace ;

Lopez Torecilla, Jose ;

Pfeffer, Raphael ;

Cutajar, Carmel Lino ;

Van der Kwast, Theodore ;

Collette, Laurence .

LANCET ONCOLOGY, 2010, 11 (11) :1066-1073

[5] Time to Prostate-Specific Antigen Nadir Independently Predicts Overall Survival in Patients Who Have Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen-Deprivation Therapy [J].

Choueiri, Toni K. ;

Xie, Wanling ;

D'Amico, Anthony V. ;

Ross, Robert W. ;

Hu, Jim C. ;

Pomerantz, Mark ;

Taplin, Mary-Ellen ;

Kantoff, Philip W. ;

Sartor, Oliver ;

Oh, William K. .

CANCER, 2009, 115 (05) :981-987

[6] ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment [J].

Clegg, Nicola J. ;

Wongvipat, John ;

Joseph, James D. ;

Tran, Chris ;

Ouk, Samedy ;

Dilhas, Anna ;

Chen, Yu ;

Grillot, Kate ;

Bischoff, Eric D. ;

Cal, Ling ;

Aparicio, Anna ;

Dorow, Steven ;

Arora, Vivek ;

Shao, Gang ;

Qian, Jing ;

Zhao, Hong ;

Yang, Guangbin ;

Cao, Chunyan ;

Sensintaffar, John ;

Wasielewska, Teresa ;

Herbert, Mark R. ;

Bonnefous, Celine ;

Darimont, Beatrice ;

Scher, Howard I. ;

Smith-Jones, Peter ;

Klang, Mark ;

Smith, Nicholas D. ;

De Stanchina, Elisa ;

Wu, Nian ;

Ouerfelli, Ouathek ;

Rix, Peter J. ;

Heyman, Richard A. ;

Jung, Michael E. ;

Sawyers, Charles L. ;

Hager, Jeffrey H. .

CANCER RESEARCH, 2012, 72 (06) :1494-1503

[7]

CULIG Z, 1994, CANCER RES, V54, P5474

[8] Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therapy in Patients With Docetaxel-Treated Castration-Resistant Prostate Cancer [J].

Danila, Daniel C. ;

Morris, Michael J. ;

de Bono, Johann S. ;

Ryan, Charles J. ;

Denmeade, Samuel R. ;

Smith, Matthew R. ;

Taplin, Mary-Ellen ;

Bubley, Glenn J. ;

Kheoh, Thian ;

Haqq, Christopher ;

Molina, Arturo ;

Anand, Aseem ;

Koscuiszka, Michael ;

Larson, Steve M. ;

Schwartz, Lawrence H. ;

Fleisher, Martin ;

Scher, Howard I. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (09) :1496-1501

[9] Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer [J].

de Bono, Johann S. ;

Scher, Howard I. ;

Montgomery, R. Bruce ;

Parker, Christopher ;

Miller, M. Craig ;

Tissing, Henk ;

Doyle, Gerald V. ;

Terstappen, Leon W. W. M. ;

Pienta, Kenneth J. ;

Raghavan, Derek .

CLINICAL CANCER RESEARCH, 2008, 14 (19) :6302-6309

[10] Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial [J].

de Bono, Johann Sebastian ;

Oudard, Stephane ;

Ozguroglu, Mustafa ;

Hansen, Steinbjorn ;

Machiels, Jean-Pascal ;

Kocak, Ivo ;

Gravis, Gwenaelle ;

Bodrogi, Istvan ;

Mackenzie, Mary J. ;

Shen, Liji ;

Roessner, Martin ;

Gupta, Sunil ;

Sartor, A. Oliver .

LANCET, 2010, 376 (9747) :1147-1154

← 1 2 3 4 5 6 →